Pulse Biosciences (PLSE) Passes AF Study Milestone As Investors Weigh An Overvalued Narrative

Pulse Biosciences (PLSE) drew investor attention after announcing that its NANOPULSE-AF Study of the nPulse System has quickly passed the enrollment midpoint, highlighting strong investigator participation and interest in its nanoPFA approach to atrial fibrillation.

See our latest analysis for Pulse Biosciences.

The NANOPULSE-AF milestone comes alongside strong share price momentum, with a 7 day share price return of 16.21% and a 90 day share price return of 68.65%. Over longer periods, total shareholder returns have also been robust, including a 3 year total shareholder return of 374.73%.

If this kind of clinical progress has your attention, it may be a good moment to look across other healthcare and bioelectric opportunities through a focused screener such as 41 healthcare AI stocks.

With Pulse Biosciences up sharply on the back of the NANOPULSE-AF progress and a market value above US$2.4b, the key issue now is whether the balance of risk and potential reward still leans toward buyers.

Most Popular Narrative: 15% Overvalued

Pulse Biosciences last closed at $35.13, which sits above the most followed fair value estimate of about $30.67 that uses a discount rate of 7.43% and a detailed set of growth and margin assumptions.

Advancing clinical programs for the nPulse cardiac surgical clamp and nPulse 360 Catheter in atrial fibrillation, including FDA IDE approval, breakthrough designation, and expanding EU feasibility data, creates a path to entry in a high value EP and cardiac surgery market that can expand the company’s addressable revenue base and long term earnings power.

Read the complete narrative.

Want to see what sits behind that kind of confidence in Pulse Biosciences? The narrative leans on rapid revenue expansion, a sharp margin shift and a valuation multiple usually reserved for high growth leaders. Curious which specific financial milestones need to line up to support that fair value.

Result: Fair Value of $30.67 (OVERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the Pulse Biosciences story still leans heavily on early stage trials and very low current revenue, so any clinical or reimbursement setbacks could quickly challenge this upbeat narrative.

Find out about the key risks to this Pulse Biosciences narrative.

Next Steps

If the Pulse Biosciences story so far feels mixed to you, this is a good time to look at the full picture and form your own view using the 1 key reward and 3 important warning signs highlighted in 1 key reward and 3 important warning signs

Looking for more investment ideas beyond Pulse Biosciences?

Do not stop at Pulse Biosciences. If you want a broader view of what is out there, use the Simply Wall Street Screener to line up your next set of ideas.

• Target steady compounding by checking out 8 dividend fortresses that may appeal if you value income alongside potential capital growth.
• Hunt for potential mispricing by reviewing 56 high quality undervalued stocks that meet strict quality and valuation filters.
• Prioritise peace of mind by focusing on 89 resilient stocks with low risk scores which may suit if you want resilience to be front and centre.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com